Csf3 (colony stimulating factor 3) - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Csf3 (colony stimulating factor 3) Rattus norvegicus
Analyze
Symbol: Csf3
Name: colony stimulating factor 3
RGD ID: 2426
Description: Enables growth factor activity. Involved in cellular response to lipopolysaccharide; positive regulation of cell population proliferation; and response to ethanol. Located in extracellular space. Biomarker of cystitis; lung disease; and middle cerebral artery infarction. Human ortholog(s) of this gene implicated in several diseases, including allergic cutaneous vasculitis; artery disease (multiple); ischemia (multiple); leukemia (multiple); and lung disease (multiple). Orthologous to human CSF3 (colony stimulating factor 3); PARTICIPATES IN cytokine mediated signaling pathway; Jak-Stat signaling pathway; malaria pathway; INTERACTS WITH 1,3,5-trinitro-1,3,5-triazinane; 2,3,7,8-tetrachlorodibenzodioxine; 2-amino-2-deoxy-D-glucopyranose.
Type: protein-coding
RefSeq Status: VALIDATED
Previously known as: colony stimulating factor 3 (granulocyte); Gcsf; granulocyte colony-stimulating factor
RGD Orthologs
Human
Mouse
Chinchilla
Bonobo
Dog
Squirrel
Pig
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr81084,157,485 - 84,159,860 (+)NCBIGRCr8
mRatBN7.21083,660,787 - 83,664,569 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1083,661,207 - 83,663,603 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1088,605,117 - 88,607,492 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01088,103,193 - 88,105,568 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01083,495,892 - 83,498,267 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01086,616,785 - 86,619,160 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1086,616,785 - 86,619,157 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01086,413,088 - 86,415,478 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41087,473,990 - 87,476,365 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11087,488,359 - 87,490,732 (+)NCBI
Celera1082,409,331 - 82,411,709 (+)NCBICelera
RH 3.4 Map10850.39RGD
Cytogenetic Map10q31NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Disease Annotations     Click to see Annotation Detail View
Acute Liver Failure  (ISO)
acute lymphoblastic leukemia  (ISO)
acute myeloid leukemia  (ISO)
agranulocytosis  (ISO)
allergic cutaneous vasculitis  (ISO)
anemia  (ISO)
angiosarcoma  (ISO)
Animal Disease Models  (ISO)
anterior ischemic optic neuropathy  (ISO)
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis  (ISO)
aplastic anemia  (ISO)
Arthralgia  (ISO)
asthma  (ISO)
B-cell lymphoma  (ISO)
bacterial pneumonia  (ISO)
bilirubin metabolic disorder  (ISO)
Bone Marrow Neoplasms  (ISO)
Brain Injuries  (ISO)
brain ischemia  (ISO)
Breast Neoplasms  (ISO)
carcinoma  (ISO)
Cardiac Fibrosis  (ISO)
Carotid Artery Injuries  (IEP)
Cerebral Hemorrhage  (ISO)
Chemical and Drug Induced Liver Injury  (ISO)
cognitive disorder  (ISO)
congestive heart failure  (ISO)
COVID-19  (ISO)
cystitis  (IEP)
depressive disorder  (ISO)
diarrhea  (ISO)
dilated cardiomyopathy  (ISO)
Disease Susceptibility  (ISO)
Drug-Induced Agranulocytosis  (ISO)
Drug-induced Neutropenia  (ISO)
Drug-Related Side Effects and Adverse Reactions  (ISO)
Endotoxemia  (ISO)
Enterobacteriaceae Infections  (IEP)
Esophageal Neoplasms  (ISO)
Experimental Arthritis  (ISO)
Experimental Colitis  (ISO)
Experimental Liver Cirrhosis  (ISO)
Fever  (ISO)
Fibrosis  (ISO)
gastrointestinal system disease  (ISO)
genetic disease  (ISO)
Head and Neck Neoplasms  (ISO)
Headache  (ISO)
heart disease  (ISO)
hepatic veno-occlusive disease  (ISO)
Hodgkin's lymphoma  (ISO)
Hyperalgesia  (ISO)
hypertrophic cardiomyopathy 25  (ISO)
Hypertrophy  (ISO)
Infarction  (ISO)
Intestinal Reperfusion Injury  (ISO)
kidney disease  (ISO)
leiomyosarcoma  (ISO)
Leukocytosis  (ISO)
leukopenia  (ISO)
limb ischemia  (ISO)
liver disease  (ISO)
Liver Injury  (ISO)
Liver Neoplasms  (ISO)
localized scleroderma  (ISO)
lung disease  (IEP,ISO)
Lung Injury  (ISO)
lung non-small cell carcinoma  (ISO)
lung small cell carcinoma  (ISO)
Lymphoma, AIDS-Related  (ISO)
melanoma  (ISO)
middle cerebral artery infarction  (IEP,ISO)
mucositis  (ISO)
multiple myeloma  (ISO)
Muscle Weakness  (ISO)
muscular disease  (ISO)
myeloid leukemia  (ISO)
myocardial infarction  (ISO)
Neoplasm Metastasis  (ISO)
Neoplasms, Second Primary  (ISO)
nervous system disease  (ISO)
neutropenia  (ISO)
Neutrophilia  (ISO)
non-Hodgkin lymphoma  (ISO)
Optic Nerve Injuries  (ISO)
Pain  (ISO)
pancytopenia  (ISO)
peripheral nervous system disease  (ISO)
pleurisy  (ISO)
Poisoning  (ISO)
pulmonary emphysema  (ISO)
pulmonary fibrosis  (ISO)
pulmonary hypertension  (ISO)
Sepsis  (ISO)
Septic Peritonitis  (ISO)
Skin Neoplasms  (ISO)
Soft Tissue Neoplasms  (ISO)
Somatosensory Disorders  (ISO)
Spinal Cord Injuries  (ISO)
Spontaneous Abortions  (ISO)
Staphylococcal Infections  (ISO)
Staphylococcal Pneumonia  (ISO)
Stevens-Johnson syndrome  (ISO)
stomatitis  (ISO)
Stroke  (ISO)
Systemic Vasculitis  (ISO)
thrombocytopenia  (ISO)
transient cerebral ischemia  (ISO)
transitional cell carcinoma  (ISO)
Transplant Rejection  (ISO)
urinary bladder cancer  (ISO)
Uterine Neoplasms  (ISO)
Ventricular Dysfunction, Left  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
1,3,5-trinitro-1,3,5-triazinane  (EXP)
1-chloro-2,4-dinitrobenzene  (ISO)
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine  (ISO)
17beta-estradiol  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,4,6-trinitrobenzenesulfonic acid  (ISO)
2-amino-2-deoxy-D-glucopyranose  (EXP)
3',5'-cyclic AMP  (ISO)
3,3',4,4',5-pentachlorobiphenyl  (ISO)
3-acetyldeoxynivalenol  (ISO)
4,4'-sulfonyldiphenol  (ISO)
4-hydroxynon-2-enal  (ISO)
4-hydroxyphenyl retinamide  (ISO)
4-phenylbutyric acid  (ISO)
7,12-dimethyltetraphene  (ISO)
7-ketocholesterol  (ISO)
acrylamide  (ISO)
agomelatine  (EXP)
aldehydo-D-glucosamine  (EXP)
all-trans-retinoic acid  (ISO)
ammonium chloride  (EXP)
amphibole asbestos  (ISO)
aripiprazole  (ISO)
arsenous acid  (ISO)
asbestos  (ISO)
azathioprine  (ISO)
benzalkonium chloride  (ISO)
benzene  (ISO)
benzo[a]pyrene  (ISO)
beta-D-glucosamine  (EXP)
bis(2-chloroethyl) sulfide  (ISO)
bisphenol A  (EXP,ISO)
bleomycin A2  (EXP)
boric acid  (ISO)
butanal  (ISO)
cadmium dichloride  (ISO)
cannabidiol  (ISO)
carbon nanotube  (ISO)
chenodeoxycholic acid  (ISO)
choline  (ISO)
cisplatin  (ISO)
clozapine  (ISO)
copper atom  (ISO)
copper(0)  (ISO)
creatine  (ISO)
crocidolite asbestos  (ISO)
crotonaldehyde  (ISO)
Cuprizon  (EXP)
deoxycholic acid  (ISO)
deoxynivalenol  (ISO)
dexamethasone  (ISO)
dextran sulfate  (ISO)
diallyl trisulfide  (ISO)
diarsenic trioxide  (ISO)
dichlorine  (EXP,ISO)
dinitrogen  (ISO)
dioxygen  (ISO)
diuron  (EXP)
doxorubicin  (EXP,ISO)
endosulfan  (ISO)
Erionite  (ISO)
erlotinib hydrochloride  (ISO)
ethanol  (ISO)
formaldehyde  (ISO)
fulvestrant  (ISO)
furosemide  (EXP)
gemcitabine  (ISO)
Genipin  (ISO)
genistein  (ISO)
gentamycin  (EXP)
gold atom  (ISO)
gold(0)  (ISO)
heparin  (EXP)
hesperetin  (ISO)
hydrogen peroxide  (ISO)
inositol  (ISO)
lipopolysaccharide  (EXP,ISO)
malathion  (ISO)
manganese(II) chloride  (EXP)
mangiferin  (ISO)
mercury dichloride  (ISO)
methotrexate  (EXP)
mirex  (EXP)
N-methyl-4-phenylpyridinium  (EXP)
N-nitrosodimethylamine  (ISO)
N1'-[2-[[5-[(dimethylamino)methyl]-2-furanyl]methylthio]ethyl]-N1-methyl-2-nitroethene-1,1-diamine  (EXP)
nickel dichloride  (ISO)
o-anisidine  (ISO)
ozone  (EXP,ISO)
paclitaxel  (ISO)
paracetamol  (ISO)
paraquat  (ISO)
pentanal  (ISO)
pentane-2,3-dione  (ISO)
phenethyl isothiocyanate  (ISO)
phloretin  (ISO)
phorbol 13-acetate 12-myristate  (ISO)
polymyxin B2  (ISO)
pomalidomide  (ISO)
progesterone  (ISO)
propanal  (ISO)
raloxifene  (ISO)
ranitidine  (EXP)
resveratrol  (ISO)
S-(1,2-dichlorovinyl)-L-cysteine  (ISO)
serpentine asbestos  (ISO)
silicon dioxide  (ISO)
sodium arsenite  (ISO)
sodium fluoride  (ISO)
sodium tungstate  (ISO)
sotorasib  (ISO)
succimer  (ISO)
tamibarotene  (ISO)
tamoxifen  (ISO)
taurocholic acid  (ISO)
terameprocol  (ISO)
tetrachloromethane  (ISO)
thalidomide  (ISO)
theophylline  (ISO)
titanium dioxide  (ISO)
trametinib  (ISO)
tremolite asbestos  (ISO)
tributylstannane  (ISO)
trichloroethene  (EXP)
troglitazone  (ISO)
valproic acid  (ISO)
verteporfin  (ISO)
XL147  (ISO)
zinc atom  (ISO)
zinc oxide  (EXP)
zinc(0)  (ISO)

Molecular Pathway Annotations     Click to see Annotation Detail View
References

References - curated
# Reference Title Reference Citation
1. Effects of granulocyte colony-stimulating factor (G-CSF) on bleomycin-induced lung injury of varying severity. Adachi K, etal., Toxicol Pathol. 2003 Nov-Dec;31(6):665-73.
2. Granulocyte colony-stimulating factor enhances host defenses against bacterial pneumonia following peritonitis in nonneutropenic rats. Attalah HL, etal., Crit Care Med. 2002 Sep;30(9):2107-14.
3. Granulocyte colony-stimulating factor enhances alpha-naphthylthiourea-induced pulmonary hypertension. Azoulay E, etal., J Appl Physiol (1985). 2003 May;94(5):2027-33. Epub 2003 Jan 10.
4. Suppression of the granulocyte colony-stimulating factor response to Escherichia coli challenge by alcohol intoxication. Bagby GJ, etal., Alcohol Clin Exp Res. 1998 Nov;22(8):1740-5.
5. Treatment of adjuvant arthritis with granulocyte-colony stimulating factor and peptide derived from heat shock protein 65. Brendolan A, etal., Cell Immunol. 2003 Jan;221(1):6-14.
6. Granulocyte colony-stimulating factor serum and urine concentrations in neutropenic neonates before and after intravenous administration of recombinant granulocyte colony-stimulating factor. Calhoun DA, etal., Pediatrics. 2000 Feb;105(2):392-7.
7. Neuroprotective effects of recombinant human granulocyte colony-stimulating factor (G-CSF) in a rat model of anterior ischemic optic neuropathy (rAION). Chang CH, etal., Exp Eye Res. 2014 Jan;118:109-16. doi: 10.1016/j.exer.2013.11.012. Epub 2013 Dec 5.
8. Co-delivery of G-CSF and EPO released from fibrin gel for therapeutic neovascularization in rat hindlimb ischemia model. Chen F, etal., Microcirculation. 2013 Jul;20(5):416-24. doi: 10.1111/micc.12037.
9. Expression of granulocyte colony-stimulating factor is induced in injured rat carotid arteries and mediates vascular smooth muscle cell migration. Chen X, etal., Am J Physiol Cell Physiol. 2005 Jan;288(1):C81-8. Epub 2004 Sep 22.
10. Granulocyte colony-stimulating factor exacerbates cardiac fibrosis after myocardial infarction in a rat model of permanent occlusion. Cheng Z, etal., Cardiovasc Res. 2008 Dec 1;80(3):425-34. doi: 10.1093/cvr/cvn202. Epub 2008 Jul 31.
11. Granulocyte colony stimulating factor neuroprotective effects on spinal motoneurons after ventral root avulsion. De Freria CM, etal., Synapse. 2012 Feb;66(2):128-41. doi: 10.1002/syn.20993. Epub 2011 Nov 3.
12. Effects of granulocyte colony stimulating factor in a nonneutropenic rodent model of Escherichia coli peritonitis. Dunne JR, etal., J Surg Res. 1996 Mar;61(2):348-54.
13. Granulocyte colony stimulating factor exacerbates antineutrophil cytoplasmic antibody vasculitis. Freeley SJ, etal., Ann Rheum Dis. 2013 Jun;72(6):1053-8. doi: 10.1136/annrheumdis-2012-202160. Epub 2012 Oct 19.
14. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
15. Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. Glaspy JA, etal., Ann Intern Med. 1988 Nov 15;109(10):789-95.
16. Cloning and expression of the cDNA encoding rat granulocyte colony-stimulating factor. Han SW, etal., Gene 1996 Oct 10;175(1-2):101-4.
17. Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques. Harousseau JL, etal., J Clin Oncol. 2000 Feb;18(4):780-7.
18. Hemorrhagic shock induces G-CSF expression in bronchial epithelium. Hierholzer C, etal., Am J Physiol. 1997 Nov;273(5 Pt 1):L1058-64.
19. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Huang C, etal., Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
20. Granulocyte colony stimulating factor attenuates hyperoxia-induced lung injury by down-modulating inflammatory responses in neonatal rats. Jeon GW, etal., Yonsei Med J. 2011 Jan 1;52(1):65-73.
21. [Effects of granulocyte colony-stimulating factor on hepatocyte apoptosis in acute liver failure: experiment with rats]. Kang W, etal., Zhonghua Yi Xue Za Zhi. 2008 Apr 8;88(14):980-4.
22. G-CSF during Escherichia coli versus Staphylococcus aureus pneumonia in rats has fundamentally different and opposite effects. Karzai W, etal., Am J Respir Crit Care Med. 1999 May;159(5 Pt 1):1377-82.
23. Leukocytoclastic vasculitis in patients with severe congenital neutropenia. Kilic SS, etal., J Trop Pediatr. 2010 Oct;56(5):359-62. doi: 10.1093/tropej/fmp140. Epub 2010 Jan 25.
24. Induction of granulocyte colony-stimulating factor mRNA by focal cerebral ischemia and cortical spreading depression. Kleinschnitz C, etal., Brain Res Mol Brain Res. 2004 Nov 24;131(1-2):73-8.
25. Delayed granulocyte colony-stimulating factor treatment in rats attenuates mechanical allodynia induced by chronic constriction injury of the sciatic nerve. Koda M, etal., Spine (Phila Pa 1976). 2014 Feb 1;39(3):192-7. doi: 10.1097/BRS.0000000000000108.
26. High-density rat radiation hybrid maps containing over 24,000 SSLPs, genes, and ESTs provide a direct link to the rat genome sequence. Kwitek AE, etal., Genome Res. 2004 Apr;14(4):750-7
27. Granulocyte-colony stimulating factor inhibits neuronal apoptosis in a rat model of diabetic cerebral ischemia. Lan X, etal., Tohoku J Exp Med. 2008 Oct;216(2):117-26.
28. Therapeutic angiogenesis with intramuscular injection of low-dose recombinant granulocyte-colony stimulating factor. Lee M, etal., Arterioscler Thromb Vasc Biol. 2005 Dec;25(12):2535-41. Epub 2005 Oct 13.
29. Granulocyte-colony stimulating factor is involved in low-dose LPS-induced neuroprotection. Li ZX, etal., Neurosci Lett. 2009 Nov 13;465(2):128-32. Epub 2009 Sep 2.
30. Improvement of heart allograft acceptability associated with recruitment of CD4+CD25+ T cells in peripheral blood by recipient treatment with granulocyte colony-stimulating factor. Liang HL, etal., Transplant Proc. 2008 Jun;40(5):1604-11. doi: 10.1016/j.transproceed.2008.02.078.
31. Granulocyte colony-stimulating factor improves survival rate and reduces concentrations of bacteria, endotoxin, tumor necrosis factor, and endothelin-1 in fulminant intra-abdominal sepsis in rats. Lundblad R, etal., Crit Care Med. 1996 May;24(5):820-6.
32. In vivo disruption of TGF-beta signaling by Smad7 in airway epithelium alleviates allergic asthma but aggravates lung carcinogenesis in mouse. Luo X, etal., PLoS One. 2010 Apr 13;5(4):e10149.
33. Granulocyte colony-stimulating factor prevents progression of monocrotaline-induced pulmonary arterial hypertension in rats. Maruyama H, etal., Circ J. 2007 Jan;71(1):138-43.
34. Relationship between the cAMP levels in leukocytes and the cytokine balance in patients surviving gram negative bacterial pneumonia. Matsumoto T, etal., J Clin Biochem Nutr. 2011 Mar;48(2):134-41. Epub 2011 Feb 26.
35. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
36. Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF). Montillo M, etal., Leuk Lymphoma. 1997 May;25(5-6):579-83.
37. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
38. Increased migration of neutrophils to granulocyte-colony stimulating factor in rat carrageenin-induced pleurisy: roles of complement, bradykinin, and inducible cyclooxygenase-2. Ogino M, etal., Inflamm Res. 1996 Jul;45(7):335-46.
39. The immunohistochemical localization of the interferon-gamma and granulocyte colony-stimulating factor receptors during early amelogenesis in rat molars. Otsuji W, etal., Arch Oral Biol. 1999 Feb;44(2):173-81.
40. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
41. Effect of recombinant human granulocyte colony stimulating factor on granulocytopenia induced by cytotoxic chemotherapy in patients with multiple myeloma. Poglod R, etal., Mater Med Pol. 1995 Jul-Sep;27(3):83-9.
42. G-CSF suppresses allergic pulmonary inflammation, downmodulating cytokine, chemokine and eosinophil production. Queto T, etal., Life Sci. 2011 May 9;88(19-20):830-8. Epub 2011 Mar 21.
43. GOA pipeline RGD automated data pipeline
44. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
45. Levels of serum granulocyte colony-stimulating factor in patients with chronic myeloid leukemia. Saitoh H and Shibata A, Leuk Lymphoma. 1993 Nov;11(5-6):443-6.
46. Neuroprotective effect of granulocyte colony-stimulating factor after focal cerebral ischemia. Schabitz WR, etal., Stroke. 2003 Mar;34(3):745-51. Epub 2003 Feb 13.
47. IFN/RBV treatment induced neutropenia and its correction with neupogen in patients with hepatitis C. Sharvadze L, etal., Georgian Med News. 2007 Jun;(147):52-5.
48. Enhancement in cognitive function recovery by granulocyte-colony stimulating factor in a rodent model of traumatic brain injury. Sikoglu EM, etal., Behav Brain Res. 2014 Feb 1;259:354-6. doi: 10.1016/j.bbr.2013.11.008. Epub 2013 Nov 14.
49. Multiplex analysis of urinary cytokine levels in rat model of cyclophosphamide-induced cystitis. Smaldone MC, etal., Urology. 2009 Feb;73(2):421-6. Epub 2008 Oct 9.
50. Granulocyte colony-stimulating factor protects the brain against experimental stroke via inhibition of apoptosis and inflammation. Solaroglu I, etal., Neurol Res. 2009 Mar;31(2):167-72. doi: 10.1179/174313209X393582.
51. The effects of recombinant human granulocyte-colony stimulating factor on vascular dysfunction and splanchnic ischaemia-reperfusion injury. Squadrito F, etal., Br J Pharmacol. 1997 Jan;120(2):333-9.
52. Granulocyte colony-stimulating factor attenuates early ventricular expansion after experimental myocardial infarction. Sugano Y, etal., Cardiovasc Res. 2005 Feb 1;65(2):446-56.
53. Antithyroid drug-induced agranulocytosis: how has granulocyte colony-stimulating factor changed therapy? Tajiri J and Noguchi S, Thyroid. 2005 Mar;15(3):292-7.
54. Implantation of fibroblasts transfected with human granulocyte colony-stimulating factor cDNA into mice as a model of cytokine-supplement gene therapy. Tani K, etal., Blood. 1989 Sep;74(4):1274-80.
55. Tentative Sequence Identification Numbers Tentative Sequence Data IDs. TIGR Gene Index, Rat Data
56. Granulocyte colony-stimulating factor administration reverses cadmium-associated inhibition of hepatocyte regeneration. Theocharis SE, etal., Eur J Gastroenterol Hepatol. 1996 Aug;8(8):805-9.
57. Anti-apoptotic effects of human granulocyte colony-stimulating factor (G-CSF) on retinal ganglion cells after optic nerve crush are PI3K/AKT-dependent. Tsai RK, etal., Exp Eye Res. 2010 May;90(5):537-45. doi: 10.1016/j.exer.2010.01.004. Epub 2010 Feb 6.
58. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. Yang Y, etal., J Allergy Clin Immunol. 2020 Apr 29. pii: S0091-6749(20)30576-5. doi: 10.1016/j.jaci.2020.04.027.
59. Effect of nartograstim, a recombinant human granulocyte colony-stimulating factor on elastase-induced emphysema in rats. Yoshimatsu A, etal., Arzneimittelforschung. 2009;59(5):248-53. doi: 10.1055/s-0031-1296393.
60. The neutrophil/Th1 lymphocyte balance and the therapeutic effect of granulocyte colony-stimulating factor in TNBS-induced colitis of rat strains. Yoshimitsu M, etal., J Interferon Cytokine Res. 2006 May;26(5):291-300.
61. Protective effect of granulocyte colony-stimulating factor on intracerebral hemorrhage in rat. Zhang L, etal., Neurochem Res. 2009 Jul;34(7):1317-23. doi: 10.1007/s11064-008-9911-6. Epub 2009 Jan 24.
62. Granulocyte colony-stimulating factor treatment ameliorates liver injury and improves survival in rats with D-galactosamine-induced acute liver failure. Zhang L, etal., Toxicol Lett. 2011 Jul 4;204(1):92-9. doi: 10.1016/j.toxlet.2011.04.016. Epub 2011 Apr 27.
63. Acute ethanol intoxication inhibits neutrophil beta2-integrin expression in rats during endotoxemia. Zhang P, etal., Alcohol Clin Exp Res. 1998 Feb;22(1):135-41.
64. Granulocyte colony-stimulating factor treatment prevents cognitive impairment following status epilepticus in rats. Zhang Y, etal., Biol Pharm Bull. 2010;33(4):572-9.
65. Brain repair by hematopoietic growth factors in a rat model of stroke. Zhao LR, etal., Stroke. 2007 Sep;38(9):2584-91. Epub 2007 Jul 26.
Additional References at PubMed
PMID:2158861   PMID:12393522   PMID:17681181   PMID:21292035   PMID:21461559   PMID:22099173   PMID:23001182   PMID:23209732   PMID:23437199   PMID:24167558   PMID:24216483   PMID:25144367  
PMID:25425079   PMID:28176642  


Genomics

Comparative Map Data
Csf3
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr81084,157,485 - 84,159,860 (+)NCBIGRCr8
mRatBN7.21083,660,787 - 83,664,569 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1083,661,207 - 83,663,603 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1088,605,117 - 88,607,492 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01088,103,193 - 88,105,568 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01083,495,892 - 83,498,267 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01086,616,785 - 86,619,160 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1086,616,785 - 86,619,157 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01086,413,088 - 86,415,478 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41087,473,990 - 87,476,365 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11087,488,359 - 87,490,732 (+)NCBI
Celera1082,409,331 - 82,411,709 (+)NCBICelera
RH 3.4 Map10850.39RGD
Cytogenetic Map10q31NCBI
CSF3
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh381740,015,440 - 40,017,813 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl1740,015,361 - 40,017,813 (+)EnsemblGRCh38hg38GRCh38
GRCh371738,171,693 - 38,174,066 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 361735,425,214 - 35,427,592 (+)NCBINCBI36Build 36hg18NCBI36
Build 341735,425,213 - 35,427,591NCBI
Celera1734,831,674 - 34,834,127 (+)NCBICelera
Cytogenetic Map17q21.1NCBI
HuRef1733,965,611 - 33,968,064 (+)NCBIHuRef
CHM1_11738,407,306 - 38,409,759 (+)NCBICHM1_1
T2T-CHM13v2.01740,879,315 - 40,881,689 (+)NCBIT2T-CHM13v2.0
Csf3
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm391198,591,287 - 98,594,457 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl1198,592,089 - 98,594,455 (+)EnsemblGRCm39 Ensembl
GRCm381198,700,183 - 98,703,631 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl1198,701,263 - 98,703,629 (+)EnsemblGRCm38mm10GRCm38
MGSCv371198,562,627 - 98,564,943 (+)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv361198,517,403 - 98,519,719 (+)NCBIMGSCv36mm8
Celera11108,355,655 - 108,357,971 (+)NCBICelera
Cytogenetic Map11DNCBI
cM Map1162.45NCBI
Csf3
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChiLan1.0 EnsemblNW_00495545114,688,181 - 14,690,126 (+)EnsemblChiLan1.0
ChiLan1.0NW_00495545114,688,181 - 14,690,126 (+)NCBIChiLan1.0ChiLan1.0
CSF3
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
NHGRI_mPanPan1-v21924,936,910 - 24,939,329 (-)NCBINHGRI_mPanPan1-v2
NHGRI_mPanPan11726,831,703 - 26,834,122 (-)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v01717,271,074 - 17,273,493 (-)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.11717,491,272 - 17,493,729 (-)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl1717,491,276 - 17,493,729 (-)Ensemblpanpan1.1panPan2
CSF3
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.1922,529,643 - 22,532,326 (-)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl922,530,698 - 22,533,108 (-)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha922,001,811 - 22,004,573 (-)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.0923,322,490 - 23,325,252 (-)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl923,323,327 - 23,325,322 (-)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.1922,095,850 - 22,098,611 (-)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.0922,355,055 - 22,357,817 (-)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.0922,479,613 - 22,482,375 (-)NCBIUU_Cfam_GSD_1.0
Csf3
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HiC_Itri_2NW_02440560221,929,893 - 21,934,092 (-)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_00493649015,142,808 - 15,144,487 (+)EnsemblSpeTri2.0SpeTri2.0 Ensembl
SpeTri2.0NW_00493649015,142,526 - 15,146,375 (+)NCBISpeTri2.0SpeTri2.0SpeTri2.0
CSF3
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl1222,333,449 - 22,338,753 (-)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.11222,333,445 - 22,335,949 (-)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.21222,732,713 - 22,734,736 (-)NCBISscrofa10.2Sscrofa10.2susScr3
CSF3
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChlSab1.11666,162,814 - 66,166,192 (-)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl1666,163,681 - 66,165,172 (-)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_02366607737,070,211 - 37,072,804 (-)NCBIVero_WHO_p1.0Vero_WHO_p1.0
Csf3
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HetGla_female_1.0 EnsemblNW_0046247953,163,009 - 3,166,594 (-)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_0046247953,162,999 - 3,167,248 (-)NCBIHetGla_female_1.0HetGla 1.0hetGla2

Variants

.
Variants in Csf3
7 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:95
Count of miRNA genes:73
Interacting mature miRNAs:85
Transcripts:ENSRNOT00000011509
Prediction methods:Miranda, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
61427Cia16Collagen induced arthritis QTL 163.2joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)10635789696121100Rat
2303118Mamtr7Mammary tumor resistance QTL 70.003mammary gland integrity trait (VT:0010552)mammary tumor growth rate (CMO:0000344)109658275104670812Rat
2301967Cm73Cardiac mass QTL 734.55heart left ventricle mass (VT:0007031)heart left ventricle weight to body weight ratio (CMO:0000530)101448701189062041Rat
631268Cia21Collagen induced arthritis QTL 213.1joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1014487011104060283Rat
2316949Gluco60Glucose level QTL 603.7blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)1014487011107057807Rat
1554317Bmd4Bone mineral density QTL 49.40.0001lumbar vertebra mineral mass (VT:0010511)volumetric bone mineral density (CMO:0001553)101981604299406971Rat
724556Pur2Proteinuria QTL 25.5urine protein amount (VT:0005160)urine protein level (CMO:0000591)102242750090627625Rat
61354Pia10Pristane induced arthritis QTL 100.01joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1023444813104060283Rat
631267Cia20Collagen induced arthritis QTL 203.2joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1023444813104060283Rat
61325Aia5Adjuvant induced arthritis QTL 50.01joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1023444813104060283Rat
1298069Bp168Blood pressure QTL 1685.5blood pressure trait (VT:0000183)systolic blood pressure (CMO:0000004)102652195798003205Rat
631542Bp82Blood pressure QTL 826.8arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)102652195798952741Rat
1331791Cm31Cardiac mass QTL 313.84606heart mass (VT:0007028)heart wet weight (CMO:0000069)1029299504107211142Rat
1576308Schws1Schwannoma susceptibility QTL 10.0041nervous system integrity trait (VT:0010566)percentage of study population developing trigeminal nerve neurilemmomas during a period of time (CMO:0002017)1040035094102359817Rat
631269Cia22Collagen induced arthritis QTL 228.9joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1040035094104060283Rat
631270Cia23Collagen induced arthritis QTL 233.9joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1040035094104060283Rat
631552Vetf2Vascular elastic tissue fragility QTL 24.50.0002aorta elastic tissue integrity trait (VT:0010556)artery internal elastic lamina non-tumorous lesion count (CMO:0001913)104114263386142633Rat
61463Bp12Blood pressure QTL 126.30.0001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)104133325886333258Rat
1298078Stresp5Stress response QTL 52.990.00025blood corticosterone amount (VT:0005345)plasma corticosterone level (CMO:0001173)1042045676104670812Rat
70188BpQTLcluster1Blood pressure QTL cluster 14.864arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)14232313287323132Rat
70188BpQTLcluster1Blood pressure QTL cluster 14.864arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)14232313287323132Rat
70188BpQTLcluster1Blood pressure QTL cluster 14.864arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)14232313287323132Rat
70188BpQTLcluster1Blood pressure QTL cluster 14.864arterial blood pressure trait (VT:2000000)pulse pressure (CMO:0000292)14232313287323132Rat
70198BpQTLcluster9Blood pressure QTL cluster 92.94arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)104232313287323132Rat
9589030Epfw9Epididymal fat weight QTL 919.240.001epididymal fat pad mass (VT:0010421)epididymal fat pad weight to body weight ratio (CMO:0000658)104444169989441699Rat
7411614Foco18Food consumption QTL 180.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)104444169989441699Rat
8694173Bw149Body weight QTL 1494.380.001body mass (VT:0001259)body weight gain (CMO:0000420)104444169989441699Rat
2300218Hpcl2Hepatic cholesterol level QTL 2liver cholesterol amount (VT:0010498)liver cholesterol level (CMO:0001597)104502965095600334Rat
631547Bp87Blood pressure QTL 874.5arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)104736947092369470Rat
1549846Scl47Serum cholesterol level QTL 473.6blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)105057470795574707Rat
70364Bp72Blood pressure QTL 72arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)105112110096121100Rat
61387Bp1Blood pressure QTL 15.1arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1051770177107211142Rat
61387Bp1Blood pressure QTL 15.1arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)1051770177107211142Rat
1359017Hrtrt21Heart rate QTL 212.4heart pumping trait (VT:2000009)heart rate (CMO:0000002)105177294096772940Rat
631530Tls3T-lymphoma susceptibility QTL 300.0001thymus integrity trait (VT:0010555)percentage of study population developing T-cell lymphomas during a period of time (CMO:0001911)105177461295600334Rat
631535Cm51Cardiac mass QTL 513heart mass (VT:0007028)calculated heart weight (CMO:0000073)105178628291669536Rat
70171Cari1Carrageenan-induced inflammation QTL 14.90.0005hypodermis integrity trait (VT:0010550)inflammatory exudate volume (CMO:0001429)1053797385107211142Rat
70164Bw21Body weight QTL 214.360.00005body mass (VT:0001259)body weight (CMO:0000012)105379749498952626Rat
1354608Cm33Cardiac mass QTL 332.8heart left ventricle mass (VT:0007031)heart left ventricle wet weight (CMO:0000071)105480929299809292Rat
2312662Slep8Serum leptin concentration QTL 80.05blood leptin amount (VT:0005667)serum leptin level (CMO:0000780)1057134272102134272Rat
2312668Scl65Serum cholesterol level QTL 650.001blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)1057134272102134272Rat
2312672Insul15Insulin level QTL 150.01blood insulin amount (VT:0001560)serum insulin level (CMO:0000358)1057134272102134272Rat
1549831Bss6Bone structure and strength QTL 64lumbar vertebra strength trait (VT:0010574)vertebra ultimate force (CMO:0001678)1057576521102576521Rat
2293698Bss43Bone structure and strength QTL 435.330.0001lumbar vertebra size trait (VT:0010518)lumbar vertebra cross-sectional area (CMO:0001689)1059209888104209888Rat
2306970Anxrr22Anxiety related response QTL 225.95fear/anxiety-related behavior trait (VT:1000241)number of periods of voluntary immobility (CMO:0001045)106134527698211570Rat
6893336Cm75Cardiac mass QTL 750.10.87heart mass (VT:0007028)heart weight to body weight ratio (CMO:0000074)106134527699703528Rat
1558643Cm44Cardiac mass QTL 444.80.0000368heart mass (VT:0007028)heart wet weight (CMO:0000069)106134527699703528Rat
2313103Bss80Bone structure and strength QTL 8020.0001tibia strength trait (VT:1000284)tibia midshaft endosteal cross-sectional area (CMO:0001716)1062057807107057807Rat
2313105Bss79Bone structure and strength QTL 791.80.0001tibia size trait (VT:0100001)tibia midshaft cross-sectional area (CMO:0001717)1062057807107057807Rat
61449Ciaa2CIA Autoantibody QTL 27.1blood autoantibody amount (VT:0003725)calculated serum anti-type 2 collagen antibody titer (CMO:0001279)1063221094107211142Rat
1357344Bp249Blood pressure QTL 2490.0001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)106674365598003205Rat
2317029Aia19Adjuvant induced arthritis QTL 192.98joint integrity trait (VT:0010548)left rear ankle joint diameter (CMO:0002149)1066978955107211142Rat
2317039Aia6Adjuvant induced arthritis QTL 64.31joint integrity trait (VT:0010548)right rear ankle joint diameter (CMO:0002150)1066978955107211142Rat
10450498Bp384Blood pressure QTL 3840.002arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1067750049107211142Rat
1642980Bp300Blood pressure QTL 300arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1068383129107211142Rat
61396Bp9Blood pressure QTL 94.80.0001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1068420376107211142Rat
2300172Bmd57Bone mineral density QTL 579.80.0001femur mineral mass (VT:0010011)volumetric bone mineral density (CMO:0001553)1069738412107211142Rat
2293646Bss25Bone structure and strength QTL 2510.960.0001femur morphology trait (VT:0000559)femur cross-sectional area (CMO:0001661)1069738412107211142Rat
2293663Bss33Bone structure and strength QTL 339.340.0001femur strength trait (VT:0010010)femur midshaft polar moment of inertia (CMO:0001669)1069738412107211142Rat
6893366Bw106Body weight QTL 1060.30.47body mass (VT:0001259)body weight (CMO:0000012)1070199100107211142Rat
70193Mcs7Mammary carcinoma susceptibility QTL 72.38mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)1072224939107211142Rat
2298548Neuinf7Neuroinflammation QTL 73.4nervous system integrity trait (VT:0010566)spinal cord RT1-B protein level (CMO:0002132)1072224939107211142Rat
2306793Ean5Experimental allergic neuritis QTL 54.7nervous system integrity trait (VT:0010566)IFNG-secreting splenocyte count (CMO:0002122)107255241693995749Rat
1358188Ept9Estrogen-induced pituitary tumorigenesis QTL 93.9pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)107345313696120911Rat
2292617Ept18Estrogen-induced pituitary tumorigenesis QTL 183.9pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)107345313696120911Rat
12880050Am10Aortic mass QTL 100.016aorta mass (VT:0002845)aorta weight to aorta length to body weight ratio (CMO:0002722)107437208484007272Rat
1579919Bp281Blood pressure QTL 2810.01arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)107437208494965338Rat
631537Oia4Oil induced arthritis QTL 4joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)107563188787055282Rat
2325836Bp346Blood pressure QTL 3460.001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)107624608584007272Rat
10450495Bp383Blood pressure QTL 3830.002arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)107624608594965338Rat
2292438Bp311Blood pressure QTL 311arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1076246085107211142Rat
1302404Cia27Collagen induced arthritis QTL 272.60.0045joint integrity trait (VT:0010548)experimental arthritis severity measurement (CMO:0001459)1076452683107211142Rat
4889492Pancm2Pancreatic morphology QTL 23.2pancreatic beta cell morphology trait (VT:0005217)ratio of insulin-positive cell area to total area of splenic region of pancreas (CMO:0001814)1076748906107211142Rat
724516Uae17Urinary albumin excretion QTL 173.6urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)107821062285220348Rat
1300107Rf18Renal function QTL 183.41urine output (VT:0003620)timed urine volume (CMO:0000260)107877551698279596Rat
1358915Stresp7Stress response QTL 73.52blood norepinephrine amount (VT:0005663)plasma norepinephrine level (CMO:0001010)107889965587307728Rat
634354Rends3Renal damage susceptibility QTL 30.05kidney blood vessel morphology trait (VT:0000530)organ lesion measurement (CMO:0000677)107981378985160854Rat
631555Bp134Blood pressure QTL 1340.001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)108051528791230079Rat
6893357Bw102Body weight QTL 1020.50.36body mass (VT:0001259)body weight (CMO:0000012)1080515287101325465Rat
2303589Bw87Body weight QTL 872body mass (VT:0001259)body weight (CMO:0000012)1081285008107211142Rat
4889948Bss91Bone structure and strength QTL 914tibia area (VT:1000281)tibia midshaft total cross-sectional area (CMO:0001715)108256485692369470Rat
2317754Glom25Glomerulus QTL 253.5urine protein amount (VT:0005160)urine protein level (CMO:0000591)1082685200107211142Rat

Markers in Region
RH94653  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21083,663,402 - 83,663,561 (+)MAPPERmRatBN7.2
Rnor_6.01086,618,960 - 86,619,118NCBIRnor6.0
Rnor_5.01086,415,278 - 86,415,436UniSTSRnor5.0
RGSC_v3.41087,476,165 - 87,476,323UniSTSRGSC3.4
Celera1082,411,509 - 82,411,667UniSTS
RH 3.4 Map10850.39UniSTS
Cytogenetic Map10q31UniSTS
PMC316809P1  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21083,662,492 - 83,663,166 (+)MAPPERmRatBN7.2
Rnor_6.01086,618,050 - 86,618,723NCBIRnor6.0
Rnor_5.01086,414,368 - 86,415,041UniSTSRnor5.0
RGSC_v3.41087,475,255 - 87,475,928UniSTSRGSC3.4
Celera1082,410,599 - 82,411,272UniSTS
Cytogenetic Map10q31UniSTS


Expression


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
High
Medium
Low 1 8
Below cutoff 1 8 1 11 1 1 1 2 26 20 5 1

Sequence


RefSeq Acc Id: ENSRNOT00000011509   ⟹   ENSRNOP00000011509
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1083,661,207 - 83,663,603 (+)Ensembl
Rnor_6.0 Ensembl1086,616,785 - 86,619,157 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000112863   ⟹   ENSRNOP00000089962
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1083,661,228 - 83,662,974 (+)Ensembl
RefSeq Acc Id: NM_017104   ⟹   NP_058800
RefSeq Status: VALIDATED
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr81084,157,485 - 84,159,860 (+)NCBI
mRatBN7.21083,661,228 - 83,663,603 (+)NCBI
Rnor_6.01086,616,785 - 86,619,160 (+)NCBI
Rnor_5.01086,413,088 - 86,415,478 (+)NCBI
RGSC_v3.41087,473,990 - 87,476,365 (+)RGD
Celera1082,409,331 - 82,411,709 (+)RGD
Sequence:
Protein Sequences
Protein RefSeqs NP_058800 (Get FASTA)   NCBI Sequence Viewer  
GenBank Protein AAC52915 (Get FASTA)   NCBI Sequence Viewer  
  EDM05943 (Get FASTA)   NCBI Sequence Viewer  
Ensembl Protein ENSRNOP00000011509
  ENSRNOP00000011509.4
  ENSRNOP00000089962.1
RefSeq Acc Id: NP_058800   ⟸   NM_017104
- Peptide Label: precursor
- UniProtKB: A6HIT8 (UniProtKB/TrEMBL),   F7FGY7 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: ENSRNOP00000011509   ⟸   ENSRNOT00000011509
RefSeq Acc Id: ENSRNOP00000089962   ⟸   ENSRNOT00000112863

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-P97712-F1-model_v2 AlphaFold P97712 1-214 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Promoters
RGD ID:13697667
Promoter ID:EPDNEW_R8192
Type:single initiation site
Name:Csf3_1
Description:colony stimulating factor 3
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Experiment Methods:Single-end sequencing.
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.01086,616,743 - 86,616,803EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:2426 AgrOrtholog
BioCyc Gene G2FUF-23349 BioCyc
Ensembl Genes ENSRNOG00000008525 Ensembl, ENTREZGENE, UniProtKB/TrEMBL
Ensembl Transcript ENSRNOT00000011509 ENTREZGENE
  ENSRNOT00000011509.4 UniProtKB/TrEMBL
  ENSRNOT00000112863.1 UniProtKB/TrEMBL
Gene3D-CATH 1.20.1250.10 UniProtKB/TrEMBL
InterPro 4_helix_cytokine-like_core UniProtKB/TrEMBL
  GCSF/MGF UniProtKB/TrEMBL
  IL-6/GCSF/MGF UniProtKB/TrEMBL
  IL6/GCSF/MGF_CS UniProtKB/TrEMBL
NCBI Gene 25610 ENTREZGENE
PANTHER GRANULOCYTE COLONY-STIMULATING FACTOR UniProtKB/TrEMBL
  PTHR10511 UniProtKB/TrEMBL
Pfam GCSF UniProtKB/TrEMBL
PhenoGen Csf3 PhenoGen
PIRSF IL6_MGF_GCSF UniProtKB/TrEMBL
PRINTS IL6GCSFMGF UniProtKB/TrEMBL
PROSITE INTERLEUKIN_6 UniProtKB/TrEMBL
RatGTEx ENSRNOG00000008525 RatGTEx
SMART IL6 UniProtKB/TrEMBL
Superfamily-SCOP 4_helix_cytokine UniProtKB/TrEMBL
TIGR TC226551
UniProt A0A8I6AAV9_RAT UniProtKB/TrEMBL
  A6HIT8 ENTREZGENE, UniProtKB/TrEMBL
  F7FGY7 ENTREZGENE, UniProtKB/TrEMBL
  P97712_RAT UniProtKB/TrEMBL


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2015-11-12 Csf3  colony stimulating factor 3  Csf3  colony stimulating factor 3 (granulocyte)  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2004-09-10 Csf3  colony stimulating factor 3 (granulocyte)    colony stimulating factor 3   Name updated 1299863 APPROVED
2002-11-06 Csf3  colony stimulating factor 3     Colony stimulating factor 3 (granulocyte)  Name updated 625702 APPROVED
2002-06-10 Csf3  Colony stimulating factor 3 (granulocyte)      Symbol and Name status set to approved 70586 APPROVED

RGD Curation Notes
Note Type Note Reference
gene_drugs used as a treatment for cyclic hematopoiesis, a severe recurrent neutropenia, in man and dogs 1298819
gene_process controls production and maintenance of neutrophils by acting on hematopoetic precursor cells 1298819